Pregabalin versus placebo: 50% seizure reduction - ITT for drug-resistant partial epilepsy.
Patient or population: patients with drug-resistant partial epilepsy | ||||||
---|---|---|---|---|---|---|
Settings: | ||||||
Intervention: Pregabalin versus placebo: 50% seizure reduction - ITT | ||||||
Outcomes | Illustrative comparative risks* (95% CI) |
Relative effect
(95% CI) |
No of Participants
(studies) |
Quality of the evidence
(GRADE) |
Comments | |
|
||||||
Assumed risk | Corresponding risk | |||||
|
||||||
Control | Pre-gabalin versus placebo: 50% seizure reduction - ITT | |||||
| ||||||
50% responders, ITT - any dose pregabalin | 15 per 100 |
40 per 100
(26 to 61) |
RR 2.61
(1.7 to 4.01) |
1868 (6 studies) |
⊕⊕⊕○ moderate 1,1 |
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;
RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
High heterogeneity statistic.
All studies sponsored by the same pharmaceutical company all reporting significant findings.